PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ogilvy Public Relations

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GVK Biosciences Strengthens Focus on 'Development' Services - Appoints Dr. Shoibal Mukherjee as Senior Vice President – Clinical Development
GVK Biosciences Strengthens Focus on 'Development' Services


NewswireToday - /newswire/ - Hyderabad, Andhra Pradesh, India, 2008/12/03 - Appoints Dr. Shoibal Mukherjee as Senior Vice President – Clinical Development.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Biosciences Private Limited (GVK BIO), one of Asia’s leading CROs, today announced the appointment of Dr. Shoibal Mukherjee to the position of Senior Vice President – Clinical Development.
“Expanding and enriching our leadership team is critical for GVK BIO’s vision of being a leading life-sciences services company," said D S Brar, Chairman, GVK BIO. "Dr. Shoibal Mukherjee has extensive experience in managing global clinical trials and will play a pivotal role in the growth of the company’s ‘Development’ services."

Prior to joining GVK BIO, Dr. Mukherjee served in Ranbaxy and Pfizer in senior positions. Dr. Mukherjee graduated as a physician and is an MD and DM in Pharmacology. Professionally trained in clinical & pharmaceutical medicine, Dr. Mukherjee has vast experience in managing Clinical Trials, Medical Affairs, Clinical Data Management, and Clinical Pharmacology. Dr. Mukherjee has authored several research papers and is a visiting faculty for established universities and medical institutions. Dr. Mukherjee is the Founding President of the Indian Society for Clinical Research and a member of several committees.

Dr. Shoibal Mukherjee is the most recent in a series of senior-level appointments at GVK BIO. Earlier this year, GVK BIO had recruited Dr. Sailendra Goswami as Vice President for Clinical Pharmacology. Dr. Goswami previously worked as CEO of Veeda Clinical Research Pvt. Ltd. and played a key role right from its inception.

GVK BIO has also strengthened its international Clinical Research Business Development team by recruiting William Harel as Vice President – Business Development, in the West Coast of USA. A PhD in Immunology, William is responsible for developing the business of Clinical Research in the US and globally. William has over 20 years of experience in various companies including Chiron Corporation, AAI Pharma and Neeman Medical International.

In addition to its well established services in Discovery Research and Informatics, GVK BIO offers Clinical Development services that span Special population studies to Phase II – IV clinical trials, Data Management, Biostatistics, Medical Writing, Pharmacovigilance, Bioequivalence studies, and Bioanalytical services.
"I am delighted to join GVK Biosciences and look forward to making GVK BIO a global clinical development service provider” said Dr.Shoibal Mukherjee on his appointment.


GVK Biosciences Asia’s leading Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai, Mumbai and Gurgaon.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Ogilvy Public Relations


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

GVK Biosciences Strengthens Focus on 'Development' Services

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Rucha Sane - 
+91 40 44344325 rucha.sane[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ogilvy Public Relations securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Ogilvy Public Relations / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  MagLar, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (